The Association Between Neprilysin Gene Polymorphisms and Alzheimer's Disease in Tibetan Population

Overview

Journal Brain Behav

Specialty Psychology

Date 2020 Dec 14

PMID 33314757

Citations 8

Authors

Siwei Chen

Dunzhu Mima

Haiqiang Jin

Qu Dan

Fei Wang

Juan Cai

Lin Shi

Huali Wang

Ailian Du

Ying Tang

Yongan Sun

Affiliations

Soon will be listed here.

Abstract

Objectives: Alzheimer's disease (AD) is a well-known neurodegenerative disease, of which the hallmark is the disposition of β-amyloid (Aβ) in the form of plaque in the brain. Neprilysin (NEP) is the major enzyme to degrade Aβ and prevent accumulation of Aβ. The present study was undertaken to elucidate the correlation between the NEP gene polymorphisms and AD in Chinese Tibetan population.

Methods: Ninety-nine sporadic AD Tibetan patients and 113 healthy Tibetan controls were enrolled in this study. The genotype frequencies and allele frequencies of multiple NEP gene loci were analyzed using the case-control association analysis.

Results: No significant correlation was found between polymorphisms of NEP gene loci (rs9829757, rs1816558, rs6776185, rs3736187, rs701109, rs989692) and the occurrence of AD in Tibetan population. However, allele C of NEP gene locus (rs701109) and allele T of gene locus (rs3736187) were possible risk factors of male AD patients in Tibetan population.

Conclusions: NEP gene loci (rs701109, rs989692, rs9829757, rs3736187, rs1816558, rs6776185) were polymorphic in Tibetan population. No difference was found between these loci but for that male gender combined with allele C of NEP gene locus (rs701109) and T of gene locus (rs3736187) might be risk factors for AD in Tibet.

Citing Articles

Association of gene polymorphisms with susceptibility to Alzheimer's disease in an Iranian population.

Khalili-Moghadam F, Nejad J, Badri T, Sadeghi M, Gharechahi J Heliyon. 2024; 10(18):e37556.

PMID: 39309779 PMC: 11416268. DOI: 10.1016/j.heliyon.2024.e37556.

Subgroup disproportionality analysis of dementia-related adverse events with sacubitril/valsartan across geographical regions.

Kim S, Kim M Sci Rep. 2024; 14(1):16408.

PMID: 39227418 PMC: 11372112. DOI: 10.1038/s41598-024-67050-5.

Risk, protective, and biomarkers of dementia in Indigenous peoples: A systematic review.

Nguyen H, Bradley K, McNamara B, Watson R, Malay R, LoGiudice D Alzheimers Dement. 2023; 20(1):563-592.

PMID: 37746888 PMC: 10917055. DOI: 10.1002/alz.13458.

Ferulic Acid Improves Synaptic Plasticity and Cognitive Impairments by Alleviating the PP2B/DARPP-32/PP1 Axis-Mediated STEP Increase and Aβ Burden in Alzheimer's Disease.

Mahaman Y, Huang F, Salissou M, Yacouba M, Wang J, Liu R Neurotherapeutics. 2023; 20(4):1081-1108.

PMID: 37079191 PMC: 10457275. DOI: 10.1007/s13311-023-01356-6.

Association between the NEP rs701109 polymorphism and the clinical efficacy and safety of sacubitril/valsartan in Chinese patients with heart failure.

Luo H, Gao L, Long H, Zhou Z, Xu S, Li F Eur J Clin Pharmacol. 2023; 79(5):663-670.

PMID: 36976322 DOI: 10.1007/s00228-023-03484-6.

References

Zhang H, Liu D, Wang Y, Huang H, Zhao Y, Zhou H . Meta-analysis of expression and function of neprilysin in Alzheimer's disease. Neurosci Lett. 2017; 657:69-76. DOI: 10.1016/j.neulet.2017.07.060. View

Braak H, Braak E . Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991; 82(4):239-59. DOI: 10.1007/BF00308809. View

Wood L, Pickering E, McHale D, Dechairo B . Association between neprilysin polymorphisms and sporadic Alzheimer's disease. Neurosci Lett. 2007; 427(2):103-6. DOI: 10.1016/j.neulet.2007.09.019. View

Fisk L, Nalivaeva N, Boyle J, Peers C, Turner A . Effects of hypoxia and oxidative stress on expression of neprilysin in human neuroblastoma cells and rat cortical neurones and astrocytes. Neurochem Res. 2007; 32(10):1741-8. DOI: 10.1007/s11064-007-9349-2. View

Ridge P, Ebbert M, Kauwe J . Genetics of Alzheimer's disease. Biomed Res Int. 2013; 2013:254954. PMC: 3741956. DOI: 10.1155/2013/254954. View

McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan E . Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984; 34(7):939-44. DOI: 10.1212/wnl.34.7.939. View

Liu Y, Studzinski C, Beckett T, Guan H, Hersh M, Murphy M . Expression of neprilysin in skeletal muscle reduces amyloid burden in a transgenic mouse model of Alzheimer disease. Mol Ther. 2009; 17(8):1381-6. PMC: 2835241. DOI: 10.1038/mt.2009.115. View

Nalivaeva N, Belyaev N, Zhuravin I, Turner A . The Alzheimer's amyloid-degrading peptidase, neprilysin: can we control it?. Int J Alzheimers Dis. 2012; 2012:383796. PMC: 3412116. DOI: 10.1155/2012/383796. View

Shao W, Peng D, Wang X . Genetics of Alzheimer's disease: From pathogenesis to clinical usage. J Clin Neurosci. 2017; 45:1-8. DOI: 10.1016/j.jocn.2017.06.074. View

10.

Chen S, Mima D, Jin H, Dan Q, Wang F, Cai J . The Association between Neprilysin gene polymorphisms and Alzheimer's disease in Tibetan population. Brain Behav. 2020; 11(3):e02002. PMC: 7994707. DOI: 10.1002/brb3.2002. View

11.

Huttenrauch M, Baches S, Gerth J, Bayer T, Weggen S, Wirths O . Neprilysin deficiency alters the neuropathological and behavioral phenotype in the 5XFAD mouse model of Alzheimer's disease. J Alzheimers Dis. 2014; 44(4):1291-302. DOI: 10.3233/JAD-142463. View

12.

Kanemitsu H, Tomiyama T, Mori H . Human neprilysin is capable of degrading amyloid beta peptide not only in the monomeric form but also the pathological oligomeric form. Neurosci Lett. 2003; 350(2):113-6. DOI: 10.1016/s0304-3940(03)00898-x. View

13.

Bayes-Genis A, Barallat J, Richards A . A Test in Context: Neprilysin: Function, Inhibition, and Biomarker. J Am Coll Cardiol. 2016; 68(6):639-653. DOI: 10.1016/j.jacc.2016.04.060. View

14.

Liu Y, Studzinski C, Beckett T, Murphy M, Klein R, Hersh L . Circulating neprilysin clears brain amyloid. Mol Cell Neurosci. 2010; 45(2):101-7. PMC: 2923273. DOI: 10.1016/j.mcn.2010.05.014. View

15.

Iwata N, Tsubuki S, Takaki Y, SHIROTANI K, Lu B, Gerard N . Metabolic regulation of brain Abeta by neprilysin. Science. 2001; 292(5521):1550-2. DOI: 10.1126/science.1059946. View

16.

DAdamio L, Shipp M, Masteller E, Reinherz E . Organization of the gene encoding common acute lymphoblastic leukemia antigen (neutral endopeptidase 24.11): multiple miniexons and separate 5' untranslated regions. Proc Natl Acad Sci U S A. 1989; 86(18):7103-7. PMC: 298003. DOI: 10.1073/pnas.86.18.7103. View

17.

Saito T, Takaki Y, Iwata N, Trojanowski J, Saido T . Alzheimer's disease, neuropeptides, neuropeptidase, and amyloid-beta peptide metabolism. Sci Aging Knowledge Environ. 2003; 2003(3):PE1. DOI: 10.1126/sageke.2003.3.pe1. View

18.

Grimm M, Mett J, Stahlmann C, Grosgen S, Haupenthal V, Blumel T . APP intracellular domain derived from amyloidogenic β- and γ-secretase cleavage regulates neprilysin expression. Front Aging Neurosci. 2015; 7:77. PMC: 4443740. DOI: 10.3389/fnagi.2015.00077. View

19.

Gough M, Parr-Sturgess C, Parkin E . Zinc metalloproteinases and amyloid Beta-Peptide metabolism: the positive side of proteolysis in Alzheimer's disease. Biochem Res Int. 2010; 2011:721463. PMC: 2989646. DOI: 10.1155/2011/721463. View

20.

Clarimon J, Munoz F, Boada M, Tarraga L, Sunyer J, Bertranpetit J . Possible increased risk for Alzheimer's disease associated with neprilysin gene. J Neural Transm (Vienna). 2003; 110(6):651-7. DOI: 10.1007/s00702-002-0807-3. View